ClinicalTrials.Veeva

Menu

Speech-derived Digital Biomarkers Study

Hackensack Meridian Health logo

Hackensack Meridian Health

Status

Completed

Conditions

Mild Cognitive Impairment (MCI)
Alzheimer Disease

Treatments

Other: The Canary Application

Study type

Interventional

Funder types

Other

Identifiers

NCT06994767
Pro2024-0418

Details and patient eligibility

About

The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.

Full description

The study aims to assess the sensitivity and specificity of an application that uses vocal biomarkers to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease. The application will use clinically validated survey instruments and voice recordings to determine the disease status of patients with MCI and Alzheimer's disease. The diagnosis developed by the application is the primary outcome variable. To determine the sensitivity and specificity, the application diagnosis will be compared against the physician's clinical diagnosis.

Enrollment

150 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and females between the ages of 50 and above
  • Willing and capable of participating in all aspects of the study
  • Willing and capable of giving informed consent
  • Diagnosis of MCI or Alzheimer's by the physician
  • For the control group: Without diagnosis of MCI or Alzheimer's or other types of dementia
  • Subjects are free of any medical condition(s) that, according to exclusion criteria, might audibly affect voice characteristics
  • Subject must be able to speak and read with fluency in the English language.

Exclusion criteria

  • All participants below 50 years

  • Failure to provide informed consent

  • Individuals with the following medical conditions will be excluded:

    i) Parkinson's disease ii) Huntington's disease iii) Cancer and active cancer treatments

  • Persons with speech characteristics (heavy accents, slurring, stuttering, etc.) that would interfere with voice recording or voice analysis

Trial design

Primary purpose

Health Services Research

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

150 participants in 3 patient groups

Mild Cognitive Impairment (MCI)
Experimental group
Description:
Patients with a mild congitive impairment
Treatment:
Other: The Canary Application
Alzheimer's Disease
Experimental group
Description:
Patients with an Alzheimer's Disease diagnosis
Treatment:
Other: The Canary Application
Healthy Volunteers
Active Comparator group
Description:
Patients without a diagnosis of MCI or Alzheimer's, or other types of dementia
Treatment:
Other: The Canary Application

Trial contacts and locations

1

Loading...

Central trial contact

Susan Dara, MPH

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems